Alzamend Neuro Inc. (ALZN)
1.12
-0.03 (-2.61%)
At close: Jan 14, 2025, 3:59 PM
1.15
2.68%
Pre-market Jan 15, 2025, 08:30 AM EST
undefined% (undefined)
| Bid | 1.15 |
| Market Cap | 6.08M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -138.31 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.18 |
| Volume | 72,356 |
| Avg. Volume (20D) | 201,349 |
| Open | 1.15 |
| Previous Close | 1.15 |
| Day's Range | 1.12 - 1.16 |
| 52-Week Range | 1.06 - 15.06 |
| Beta | undefined |
About ALZN
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neu...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 15, 2021
Employees 4
Stock Exchange NASDAQ
Ticker Symbol ALZN
Website https://www.alzamend.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ALZN stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 2757.14% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
4 months ago ·
Source
+186.76%
Alzamend Neuro shares are trading higher after the...
Unlock content with
Pro Subscription
8 months ago ·
Source
+11.74%
Alzamend Neuro shares are trading higher after the company entered into a Securities Purchase Agreement with an institutional investor.
